ENV 375
Alternative Names: ENV-375Latest Information Update: 12 Feb 2026
At a glance
- Originator Envisagenics
- Class Antidementias; Antiparkinsonians; Oligonucleotides
- Mechanism of Action RNA splicing modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
- Research Alzheimer's disease; Frontotemporal dementia; Parkinson's disease
Most Recent Events
- 12 Feb 2026 Envisagenics has patent protection for systems and methods for analysis of alternative splicing in Australia
- 12 Feb 2026 Envisagenics has patents pending for systems and methods for analysis of alternative splicing in Japan, China, Europe, Canada and USA
- 04 Feb 2026 Early research in Alzheimer's disease in USA (Parenteral) before February 2026 (Envisagenics pipeline, February 2026)